Giant Cell Tumor of Bone: 413 Patients, Analysis of Recurrence Rate and Local Recurrence Risk Factors

Description

In this presentation, Dr. Ahmed Aoude discusses a retrospective study at Mount Sinai Hospital that evaluated the recurrence rates of giant cell tumors, a type of benign aggressive bone tumor prevalent in younger patients, particularly around large joints. The study involved 354 patients treated between 1989 and 2017, excluding those who received denosumab or had smaller joints involved. Aoude highlights the aim of the study to assess local recurrence and identify risk factors associated with it.



The study analyzed various patient and tumor characteristics, including lesion size, and categorized patients based on the type of surgical intervention received (e.g., en-bloc resection vs. aggressive curettage). A total local recurrence rate of 15% was found, with higher rates among patients who underwent curettage compared to those who had en-bloc resections. A significant finding was that younger patients (under 30 years) exhibited a higher local recurrence rate, while factors such as gender and tumor size showed no significance.



The results aim to inform treatment decisions for giant cell tumors, prioritizing joint salvage even when faced with greater recurrence rates, suggesting relative success in maintaining joint functionality post-treatment. Aoude concludes with a call for careful consideration of treatment approaches to optimize outcomes for these patients.

Specialties